Business Description
Psyence Biomedical Ltd. is a Toronto-based company working to develop medicines derived from naturally occurring psilocybin to help patients dealing with serious emotional and psychological conditions. Its primary focus is on people receiving end-of-life care who have been diagnosed with incurable cancer, particularly those struggling with anxiety, depression, grief, and adjustment disorder. The company's lead treatment, PEX010, is currently undergoing Phase IIb clinical trials in partnership with iNGENu Pty Ltd, and it also works with PsyLabs on the production of Ibogaine. Psyence Biomedical operates as part of the broader Psyence Group Inc.
